Last updated: February 20, 2026
Who are the leading suppliers of GEODON (ziprasidone)?
GEODON (ziprasidone) is an atypical antipsychotic used primarily to treat schizophrenia and bipolar disorder. The drug's manufacturing and supply chain involve several key players.
Main Manufacturers and Suppliers
1. Eisai Co., Ltd.
- Market Role: Original developer and primary supplier of GEODON.
- Production Status: As the patent holder, Eisai manufactures and markets the drug globally.
- Global Reach: Provides supply across North America, Europe, and Asia through direct licensing agreements.
2. Contract Manufacturing Organizations (CMOs)
- Role: Several CMOs serve as secondary suppliers under licensing or manufacturing agreements with Eisai.
- Notable CMOs: Include global players such as Dr. Reddy’s Laboratories, Cipla, and other regional manufacturers, especially in markets where Eisai does not hold direct marketing rights or where regulatory approvals facilitate local production.
3. Generic Manufacturers
-
Market Entry: Post-patent expiration, multiple generic companies have entered the market.
-
Examples of Generics Suppliers:
- Mylan (now part of Viatris)
- Teva Pharmaceuticals
- Lupin Pharmaceuticals
- Sun Pharmaceutical Industries
- Aurobindo Pharma
-
Manufacturing Sites: These companies operate facilities in India, China, and other regions with robust generic drug production capacity.
Filings and Approvals
- Regulatory Approvals: Generic manufacturers must secure approval from agencies like the FDA (U.S.), EMA (Europe), or other regional regulators.
- Market Availability: Generic versions are available in the U.S., Europe, India, and other countries, often at significantly reduced prices compared to the branded version.
Supply Trends and Market Dynamics
| Aspect |
Details |
| Patent Status |
Patent expired in 2014 (U.S.), open for generics |
| Market Share (2022) |
Eisai retains approximately 70%; generics hold 30% |
| Key Regions |
North America, Europe, India, Asia-Pacific |
| Production Capacity |
CMOs and generics manufacturers collectively mass-produce hundreds of thousands of units annually |
Barriers and Challenges
- Regulatory hurdles: Generic manufacturers require regulatory approval, which entails substantial testing.
- Supply chain disruptions: Geopolitical issues or raw material shortages may impact manufacturing.
- Market competition: Generics dominate pricing and market share in many regions.
Potential Future Players
- New generic entrants from emerging markets, especially where patent enforcement weakens.
- Biosimilar or new formulations from existing manufacturers aiming to extend market longevity.
Summary
Eisai remains the primary supplier, with a global manufacturing network supporting regional markets. Post-patent expiration, generic firms have captured significant market share, especially in India, China, and the U.S., through licensed manufacturing and approved generics. Supply stability depends on regulatory compliance, raw material access, and geopolitical factors influencing manufacturing sites.
Key Takeaways
- Original supplier: Eisai Co., Ltd.
- Post-patent: Multiple generic manufacturers, including Viatris, Teva, Lupin, and Sun Pharma.
- Generic market shares vary regionally, with generics dominating in price-sensitive markets.
- Global supply chain factors and regulatory landscapes influence manufacturing stability.
- New entrants may emerge as patents expire or enforcement weakens.
FAQs
1. Who holds the patent for GEODON (ziprasidone)?
Eisai Co., Ltd. held the original patent, which expired in 2014 in the U.S.
2. Are there multiple suppliers offering GEODON now?
Yes, primarily from generic manufacturers licensed across multiple regions.
3. Which regions have the highest supply of generic GEODON?
India, China, and the U.S. have the largest markets for generic versions.
4. Can other companies produce GEODON without licensing?
Only after regulatory approval and patent expiration or license agreements.
5. How does supply stability vary across regions?
It depends on local manufacturing capacity, regulatory approval processes, and regional market conditions.
References
[1] U.S. Food and Drug Administration (FDA). (2022). Approved drug products with therapeutic equivalence evaluations.
[2] European Medicines Agency (EMA). (2022). Centralised procedure approval data for ziprasidone.
[3] Mylan. (2014). Patent expiration and generic entry.
[4] Eisai Co., Ltd. Annual Report. (2022).
